SURGICAL
hamburger
product photo

FULL, BRILLIANT VISION

The TECNIS® CL IOL delivers ultraviolet-absorbing posterior technology and corrects for corneal spherical aberrations — all in a foldable silicone design. 

Three-piece silicone TECNIS® IOLs offer:

  • Reduction of spherical aberration to essentially zero
  • Full transmission of visible light
  • Effective UV protection
  • Proven biocompatibility1

Best Case Visual Acuity Results2

AGE

N

Percent of “Best Case” Patients with Visual Acuity of 20/40 or Better

TECNIS® CL 3-Piece IOL

FDA Grid

<60

11

100%

96.9%

60–69

73

100%

93.8%

70–79

139

98%

94.9%

> 79

52

98%

87.9%

Total

275

99%

94.0%

TECNIS® CL Silicone IOL (Z9002)1

OPTIC CHARACTERISTICS

Powers:

+5.0 D to 30.0 D in 0.5 diopter increments

Diameter:

6.0 mm

Shape:

Biconvex, anterior aspheric surface, OptiEdge Design

Material:

UV-blocking SLM-2 Silicone

Refractive Index:

1.46 at 35° C

CONSTANTS

Nominal (theoretically calculated)

Laser Interference Biometry

A-Constant:

118.7

118.7

AC Depth:

5.40 mm

5.40 mm

Surgeon Factor:

1.62 mm

1.62 mm

HAPTIC CHARACTERISTICS

Overall Length:

13.0 mm

Style:

Modified C

Material:

60% Blue-core Polymethylmethacrylate (PMMA) Monofilament

Angle:

10˚

Average Weight in Air:

19.3 mg


LENS INSERTION

Recommended insertion instruments:

REFERENCES

  1. Internal Data. Abbott Vision. 2002.
  2. TECNIS® CL [package insert]. Santa Ana, Calif. Abbott Medical Optics Inc.

IMPORTANT SAFETY INFORMATION FOR TECNIS® CL 3-PIECE IOLs 

Rx Only

INDICATIONS

TECNIS® CL Silicone intraocular lenses are indicated for primary implantation for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction or phacoemulsification. These devices are intended to be placed in the capsular bag.

WARNINGS

Physicians considering lens implantation under any of the conditions described in the Directions for Use labeling should weigh the potential risk/benefit ratio prior to implanting a lens. These conditions include: patients with recurrent severe anterior or posterior segment inflammation or uveitis, patients in whom the intraocular lens may affect the ability to observe, diagnose or treat posterior segment diseases, surgical difficulties at the time of cataract extraction, which may increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled positive pressure or significant vitreous prolapse or loss), a distorted eye due to previous trauma or developmental defect in which appropriate support of the IOL is not possible, circumstances that would result in damage to the endothelium during implantation, suspected microbial infection, patients in whom neither the posterior capsule nor the zonules are intact enough to provide support for the IOL, since the clinical study of parent lens model 911A was conducted with the lens implanted in the capsular bag, there are insufficient clinical data to demonstrate the safety and efficacy for placement in the ciliary sulcus, children under the age of 2 years are not suitable candidates for intraocular lenses, the use of silicone lenses in patients with current vitreoretinal disease or those who are at high risk for future vitreoretinal disease that may require silicone oil as part of therapy should be reconsidered. AMO IOLs are single-use medical devices that are labeled with instructions for use and handling to minimize exposure to conditions that may compromise the product, patient, or the user. The reuse/resterilization/reprocessing of AMO single-use medical devices may result in physical damage to the medical device, failure of the medical device to perform as intended, and patient illness or injury due to infection, inflammation, and/or illness due to product contamination, transmission of infection, and lack of product sterility.

PRECAUTIONS

Do not resterilize the lens as this can produce undesirable side effects. Do not soak or rinse the intraocular lens with any solution other than sterile balanced salt solution or sterile normal saline. Do not store the lens in direct sunlight or at a temperature greater than 45°C. Do not autoclave the intraocular lens. Avoid exposure to volatile chemicals. Do not reuse the lens.

ADVERSE EVENTS

The most frequently reported adverse event that occurred during the clinical trials of the parent lens models for the TECNIS® CL intraocular lens was corneal edema (upper and lower corneal edema), which occurred at a combined rate of 10.9%. The second most frequent adverse event was iritis, which occurred at a rate of 7.9%. Macular edema was the third most frequently reported adverse event, which occurred at a rate of 3.8%. Other reported reactions occurring in less than 2% of patients were hyphema, secondary glaucoma, cyclitic membrane, vitritis, surgical intervention (penetrating keratoplasty, lens replacement, and lens removal, lens repositioning, wound leak repair, and focal laser therapy), corneal decompensation and endophthalmitis.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR THE UNFOLDER® SILVER SERIES IMPLANTATION SYSTEM

Rx Only

INDICATIONS

The UNFOLDER® Silver Series Implantation System is used to fold and assist in inserting CLARIFLEX, PHACOFLEX II, CeeOn, TECNIS® Silicone, and ARRAY Silicone ≤ 24.0 D IOLs only, into the eye. 

WARNINGS

The UNFOLDER® Silver Series Implantation System should only be used with silicone IOLs. Do not use this device or any of its components with any other lens. If the cartridge tip is cracked or split prior to implantation, do not use. 

See Full Indications and Important Safety Information.

ATTENTION

Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

PP2017MLT0200

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. All other trademarks are the intellectual property of their respective owners.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2017 Abbott Laboratories Inc. Abbott Park, Illinois, USA. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. All other trademarks are the intellectual property of their respective owners.

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. All other trademarks are the intellectual property of their respective owners.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?